论文部分内容阅读
目的:探讨参麦注射液联合比索洛尔治疗冠心病心力衰竭患者的临床疗效分析。方法:选择我院2010年1月—2011年6月收治的98例冠心病心力衰竭患者,采用随机临床对照观察方法,参麦注射液联合比索洛尔治疗48例慢性充血性心力衰竭的患者为治疗组,对照组给予强心、扩血管、血管紧张素转换酶抑制剂、利尿等基础治疗,治疗组在抗心力衰竭常规治疗的基础上给予参麦注射液30~40 mL加入5%葡萄糖注射液250 mL,静滴,1次/d,同时给予比索洛尔,从1.25 mg的初始剂量开始口服,视患者心功能状况1~2周递增1次剂量,达到5 mg/d后,1月递增1次。根据患者的耐受情况和临床表现,可加靶剂量10 mg/d,达到此剂量即不再加量。测定治疗前后左心室收缩末期容积(LVESV)、左室射血分数(LVEF)、左心室舒张末期容积(LVEDV)变化,并进行临床疗效分析。结果:与对照组疗效比较,治疗组总有效率高于对照组,两组比较有显著性差异,有统计学意义(P<0.05)。两组治疗后LVEF、LVESV、LVEDV较治疗前均明显改善(P<0.05),治疗后,与对照组LVESV、LVEF、LVEDV比较,治疗组各项指标明显优于对照组,差异有统计学意义(P<0.05)。结论:参麦注射液联合比索洛尔治疗能有效改善CHF患者心功能,值得在临床上推广。
Objective: To investigate the clinical efficacy of Shenmai injection combined with bisoprolol in the treatment of patients with heart failure of coronary heart disease. Methods: A total of 98 patients with CHD who were admitted to our hospital from January 2010 to June 2011 were enrolled in this study. Randomized controlled clinical observation was conducted in 48 patients with chronic congestive heart failure treated with Shenmai injection combined with bisoprolol The treatment group and the control group were given basic treatment of cardioplegia, vasodilator, angiotensin converting enzyme inhibitor and diuretic. The treatment group was given 30 ~ 40 mL of Shenmai injection on 5% glucose injection Liquid 250 mL, intravenous infusion, once / d, given bisoprolol, starting from the initial dose of 1.25 mg, depending on the patient’s cardiac function 1 to 2 weeks increased by 1 dose, reaching 5 mg / d, January Increment 1 times. According to the patient’s tolerance and clinical manifestations, plus the target dose of 10 mg / d, to achieve this dose is no longer add. The left ventricular end-systolic volume (LVESV), left ventricular ejection fraction (LVEF) and left ventricular end-diastolic volume (LVEDV) were measured before and after treatment, and the clinical curative effect was analyzed. Results: Compared with the control group, the total effective rate in the treatment group was higher than that in the control group. There was significant difference between the two groups (P <0.05). After treatment, LVEF, LVESV and LVEDV in both groups were significantly improved compared with those before treatment (P <0.05). After treatment, LVESV, LVEF and LVEDV in the treatment group were significantly better than those in the control group (P <0.05). Conclusion: Shenmai injection combined with bisoprolol treatment can effectively improve the cardiac function in patients with CHF, it is worth clinical promotion.